dabigatran has been researched along with spironolactone in 2 studies
Studies (dabigatran) | Trials (dabigatran) | Recent Studies (post-2010) (dabigatran) | Studies (spironolactone) | Trials (spironolactone) | Recent Studies (post-2010) (spironolactone) |
---|---|---|---|---|---|
3,887 | 261 | 3,490 | 7,222 | 960 | 1,923 |
Protein | Taxonomy | dabigatran (IC50) | spironolactone (IC50) |
---|---|---|---|
Chain A, Mineralocorticoid receptor | Homo sapiens (human) | 0.049 | |
Chain A, Mineralocorticoid receptor | Homo sapiens (human) | 0.049 | |
Estrogen receptor | Homo sapiens (human) | 5.702 | |
Glucocorticoid receptor | Homo sapiens (human) | 4.0745 | |
Progesterone receptor | Homo sapiens (human) | 1.675 | |
Glycine receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 1.9025 | |
Mineralocorticoid receptor | Homo sapiens (human) | 0.0315 | |
Androgen receptor | Homo sapiens (human) | 0.3585 | |
Androgen receptor | Rattus norvegicus (Norway rat) | 0.406 | |
Glycine receptor subunit beta | Rattus norvegicus (Norway rat) | 1.9025 | |
Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | 1.9025 | |
Glycine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | 1.9025 | |
Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 6.92 | |
Cytochrome P450 2C19 | Homo sapiens (human) | 3 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA | 1 |
Andreev, DA; Gappoeva, ZK; Giliarov, MIu; Sychev, DA | 1 |
2 other study(ies) available for dabigatran and spironolactone
Article | Year |
---|---|
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs | 2013 |
[Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Agents; Dabigatran; Drug Interactions; Drug Therapy, Combination; Heart Failure; Hemorrhage; Humans; Male; Renal Insufficiency, Chronic; Spironolactone; Treatment Outcome; Withholding Treatment | 2013 |